$2.05
-0.07-3.3%
Last update: Nov 10, 4:09 PM
Adagene Inc
ADAGNASDAQ
Adagene rose 31.7% from $1.61 to $2.12, ahead of the S&P 500's +10.0%. Its worst day was Nov 5 (−16.2%), and its low came Jan 9 at $1.53.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Adagene closed at its lowest level of the year, 5.0% below where the year started.
−7.3% · S&P 500 +0.7%
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to
Story events cover the past 12 months · Times ET
+22.7%, the year's best day · S&P 500 0.0%
Adagene shares rose 21.2%, while the S&P 500 fell 0.1%.
+21.2% · S&P 500 −0.1%
EPS of $-0.24 beat the $-0.61 estimate on $7.7M revenue (est. $1.7M).
−13.4% · S&P 500 +0.1%
Adagene closed at its highest level of the year, 196.9% above where the year started.
+13.8% · S&P 500 −0.1%
EPS of $-0.20 missed the $-0.14 estimate on $1.6M revenue.
−3.6% · S&P 500 +0.3%
Where it ended: a close of $2.12 on Nov 9, 2026.
Nothing in the past 12 months.
All ADAG dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ADAG and SPY from Benzinga historical bars. Not investment advice.
